Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes

Obstetrics and Gynecology

Volumn 130, Issue 1, 2017, Pages 10-28

  Reddy, Uma M ^a   Davis, Jonathan M ^b   Ren, Zhaoxia ^c   Greene, Michael F ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ANALGESIA; CHILD HEALTH; CHILDHOOD; HUMAN; NEONATAL ABSTINENCE SYNDROME; OPIATE ADDICTION; PERINATAL PERIOD; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL CARE; PRENATAL EXPOSURE; PRENATAL SCREENING; PRIORITY JOURNAL; PUERPERIUM; REVIEW; CHILD; CHILD OF IMPAIRED PARENTS; CONSENSUS DEVELOPMENT; FEMALE; NEWBORN; OBSTETRICS; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATIONS; UNITED STATES;

CHILD; CHILD OF IMPAIRED PARENTS; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OBSTETRICS; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; UNITED STATES;

EID: 85020485840     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000002054     Document Type: Review

References (144)

1. Centers for Disease Control and Prevention. Vital signs: Prescription painkiller overdoses: A growing epidemic, especially among women. Available at: Http://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/. Retrieved October 11, 2016.
2. International Narcotics Control Board. Report of the International Narcotics Control Board for 2010. New York (NY): United Nations; 2010.
3. Ailes EC, Dawson AL, Lind JN, Gilboa SM, Frey MT, Broussard CS, et al. Opioid prescription claims among women of reproductive age-United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2015;64:37-41.
4. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
5. Schuckit MA. Treatment of opioid-use disorders. N Engl J Med 2016;375:357-68.
6. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:667.
7. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-40.
8. Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015;135:842-50.
9. Pert CB, Pasternak G, Snyder SH. Opiate agonists and antagonists discriminated by receptor binding in brain. Science 1973;182:1359-61.
10. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66.
11. Chasnoff IJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med 1990;322:1202-6.
12. Substance abuse reporting and pregnancy: The role of the obstetrician-gynecologist. Committee Opinion No. 473. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;117:200-1.
13. Guttmacher Institute. State laws and policies: Substance abuse during pregnancy. Available at: Https://www.guttmacher.org/state-policy/explore/substance-abuse-during-pregnancy. Retrieved September 21, 2016.
14. Alcohol abuse and other substance use disorders: Ethical issues in obstetric and gynecologic practice. Committee Opinion No. 633. American College of Obstetrician and Gynecologists. Obstet Gynecol 2015;125:1529-37.
15. El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol 2003;23: 354-60.
16. U.S. Preventive Services Task Force. Final recommendation statement: Drug use, illicit: Screening. Available at: Https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/drug-use-illicit-screening. Retrieved September 21, 2016.
17. Opioid abuse, dependence, addiction in pregnancy. Committee Opinion No. 524. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:1070-6.
18. Wolff K, Farrell M, Marsden J, Monteiro MG, Ali R, Welch S, et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 1999;94: 1279-98.
19. Strano-Rossi S. Methods used to detect drug abuse in pregnancy: A brief review. Drug Alcohol Depend 1999;53:257-71.
20. Yonkers KA, Howell HB, Gotman N, Rounsaville BJ. Selfreport of illicit substance use versus urine toxicology results from at-risk pregnant women. J Subst Use 2011;16:372-389.
21. Harper RG, Solish GI, Purow HM, Sang E, Panepinto WC. The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants. Pediatrics 1974;54: 300-5.
22. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. The narcotic-dependent mother: Fetal and neonatal consequences. Early Hum Dev 1977;1:159-69.
23. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25:139-51.
24. Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991;23: 191-201.
25. Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975;122:43-6.
26. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004.
27. Albright B, de la Torre L, Skipper B, Price S, Abbott P, Rayburn W. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011;41:347-53.
28. Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002;100:1244-9.
29. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003;189:312-7.
30. Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, et al. Methadone and perinatal outcomes: A prospective cohort study. Addiction 2012;107:1482-92.
31. Jones HE, Jansson LM, O'Grady KE, Kaltenbach K. The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations. Neurotoxicol Teratol 2013;39:110-5.
32. Pizarro D, Habli M, GrierM, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat 2011;40:295-8.
33. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010;105:2071-84.
34. Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012;35: 441-60.
35. Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin North Am 2014;41:241-53.
36. Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011;5:254-63.
37. Alto WA, O'Connor AB. Management of women treated with buprenorphine during pregnancy. Am J Obstet Gynecol 2011; 205:302-8.
38. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: Review of human and animal data. Curr Neuropharmacol 2008;6:125-50.
39. Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, et al. Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat 2013;45:287-92.
40. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-7.
41. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-31.
42. Lester BM, Lagasse LL. Children of addicted women. J Addict Dis 2010;29:259-76.
43. Shiu JR, Ensom MH. Dosing and monitoring of methadone in pregnancy: Literature review. Can J Hosp Pharm 2012;65:380-6.
44. Jansson LM, Dipietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehaviour. JMatern Fetal Neonatal Med 2009;22:29-35.
45. McCarthy JJ, Leamon MH, Willits NH, Salo R. The effect of methadone dose regimen on neonatal abstinence syndrome. J Addict Med 2015;9:105-10.
46. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs methadone taper during pregnancy: Maternal and neonatal outcomes. Am J Addict 2008;17:372-86.
47. Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, et al. Induction of pregnant women onto opioidagonist maintenance medication: An analysis of withdrawal symptoms and study retention. Drug Alcohol Depend 2013; 132:329-34.
48. Holbrook AM, Baxter JK, Jones HE, Heil SH, Coyle MG, Martin PR, et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction 2012;107(suppl 1):83-90.
49. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphineexposed neonates. Addiction 2012;107(suppl 1):53-62.
50. Gaalema DE, Heil SH, Badger GJ, Metayer JS, Johnston AM. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend 2013;133:266-9.
51. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: Systematic review and meta-analysis. Am J Epidemiol 2014;180:673-86.
52. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. Drug Alcohol Depend 2003;70(suppl):S87-101.
53. McNicholas LF, Holbrook AM, O'Grady KE, Jones HE, Coyle MG, Martin PR, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction 2012;107 (suppl 1):91-7.
54. Komaromy M, Buser R, Silver H, Hayes L, Bohan J, Duhigg D, et al. New Mexico treatment guidelines for medical providers who treat opioid addiction using buprenorphine. Santa Fe (NM): New Mexico Behavioral Health Collaborative; 2012.
55. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioiddependent pregnant women: A comprehensive review. Addiction 2012;107(suppl 1):5-27.
56. Elkader A, Sproule B. Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44:661-80.
57. American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase (MD): American Society of Addiction Medicine; 2015.
58. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Geneva (Switzerland): World Health Organization; 2014.
59. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013;22:252-4.
60. Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, MorroneWR, et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes. Subst Abuse 2013;7:61-74.
61. Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015;125: 363-8.
62. Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, et al. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open 2016;6:e011774.
63. Leslie DL, Milchak W, Gastfriend DR, Herschman PL, Bixler EO, Velott DL, et al. Effects of injectable extendedrelease naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. Am J Addict 2015;24:265-70.
64. Cousins SJ, Radfar SR, Crevecoeur-MacPhail D, Ang A, Darfler K, Rawson RA. Predictors of continued use of extended-released naltrexone (XR-NTX) for opioid-dependence: An analysis of heroin and non-heroin opioid users in Los Angeles County. J Subst Abuse Treat 2016;63:66-71.
65. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med 2016;374:1232-42.
66. Saia KA, Schiff D, Wachman EM, Mehta P, Vilkins A, Sia M, et al. Caring for pregnant women with opioid use disorder in the USA: Expanding and improving treatment. Curr Obstet Gynecol Rep 2016;5:257-263.
67. Jones HE, Chisolm MS, Jansson LM, Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: The case for a considered and measured approach to research. Addiction 2013;108:233-47.
68. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92: 854-8.
69. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24:363-7.
70. Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013;209:267.e1-5.
71. Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O'Grady KE, Jones HE. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes. Subst Abuse Rehabil 2012;3(suppl 1):17-25.
72. Bell J, Towers CV, Hennessy MD, Heitzman C, Smith B, Chattin K. Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol 2016;215:374.e1-6.
73. Blinick G, Wallach RC, Jerez E, Ackerman BD. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol 1976;125:135-42.
74. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011;204:314.e1-11.
75. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol 2013;122:838-44.
76. Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: A systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016;111:2115-28.
77. Parikh R, Hussain T, Holder G, Bhoyar A, Ewer AK. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F141-3.
78. Archie CL, Lee MI, Sokol RJ, Norman G. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989;74:254-5.
79. Levine AB, Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995;15:229-31.
80. Anyaegbunam A, Tran T, Jadali D, Randolph G, Mikhail MS. Assessment of fetal well-being in methadone-maintained pregnancies: Abnormal nonstress tests. Gynecol Obstet Invest 1997;43:25-8.
81. BenningfieldMM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, medical impairment in opioid dependent pregnant women. Am J Addict 2010; 19:416-21.
82. Ouimette PC, Kimerling R, Shaw J, Moos RH. Physical and sexual abuse among women and men with substance use disorders. Alcohol Treat Q 2008;18:7-17.
83. Terplan M, McNamara EJ, Chisolm MS. Pregnant and nonpregnant women with substance use disorders: The gap between treatment need and receipt. J Addict Dis 2012;31:342-9.
84. Terplan M, Longinaker N, Appel L. Women-centered drug treatment services and need in the United States, 2002-2009. Am J Public Health 2015;105:e50-4.
85. Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: The role of obstetric providers. Am J Obstet Gynecol 2014;210:302-10.
86. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006;144:127-34.
87. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007;110: 261-6.
88. Meyer M, Paranya G, Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010;14:939-43.
89. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: A knowledge synthesis for better treatment for women and neonates. Addiction 2008;103:1429-40.
90. Substance Abuse and Mental Health Services Administration. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2005.
91. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep 2016;65:1-49.
92. Kantor TG, Cantor R, Tom E. A study of hospitalized surgical patients on methadone maintenance. Drug Alcohol Depend 1980;6:163-73.
93. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol 2012;8:335-40.
94. Bateman BT, Huybrechts KF, Booth J, Briggs H, Flood P, Bauer M, et al. Opioid use following discharge after cesarean delivery. Pharmacoepidemiol Drug Saf 2016;25:567.
95. Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, et al. Persistent opioid use following cesarean delivery: Patterns and predictors among opioid-naive women. Am J Obstet Gynecol 2016;215:353.e1-18.
96. Gopman S. Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin North Am 2014;41: 213-28.
97. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: A review of the literature and current management guidelines. J Hum Lact 2004;20:62-71.
98. Demirci JR, Bogen DL, Klionsky Y. Breastfeeding and methadone therapy: The maternal experience. Subst Abus 2015;36: 203-8.
99. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006;117:e1163-9.
100. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008;121:106-14.
101. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: Factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116:665-71.
102. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care 2011;11:282-90.
103. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012;41:180-90.
104. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 2013; 102:1060-6.
105. Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009;25:199-205.
106. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
107. Ballard JL. Treatment of neonatal abstinence syndrome with breast milk containing methadone. J Perinatal Neonatal Nurs 2002;15:76-85.
108. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: Maternal and neonatal outcomes. Am J Obstet Gynecol 2005;193:606-10.
109. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010;5:159-64.
110. O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health 2013;58:383-8.
111. Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 2009;4:225-8.
112. Jansson LM, Spencer N, McConnell K, Velez M, Tuten M, Harrow CA, et al. Maternal buprenorphine maintenance and lactation. J Hum Lact 2016;32:675-681.
113. Heil SH, Jones HE, Arria A, Kaltenbach K, CoyleM, Fischer G, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 2011;40:199-202.
114. Black KI, Stephens C, Haber PS, Lintzeris N. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol 2012;52: 146-50.
115. Armstrong KA, Kennedy MG, Kline A, Tunstall C. Reproductive health needs: Comparing women at high, drug-related risk of HIV with a national sample. J Am Med Womens Assoc (1972) 1999;54:65-70, 78.
116. Terplan M, Lawental M, Connah MB, Martin CE. Reproductive health needs among substance use disorder treatment clients. J Addict Med 2016;10:20-5.
117. Armstrong KA, Kenen R, Samost L. Barriers to family planning services among patients in drug treatment programs. Fam Plann Perspect 1991;23:264-6, 270-1.
118. Ralph N, Spigner C. Contraceptive practices among female heroin addicts. Am J Public Health 1986;76:1016-7.
119. Morrison CL, Ruben SM, Beeching NJ. Female sexual health problems in a drug dependency unit. Int J STD AIDS 1995;6: 201-3.
120. Terplan M, Hand DJ, Hutchinson M, Salisbury-Afshar E, Heil SH. Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review. Prev Med 2015;80:23-31.
121. Sinha C, Guthrie KA, Lindow SW. A survey of postnatal contraception in opiate-using women. J Fam Plann Reprod Health Care 2007;33:31-4.
122. Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: Do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012;206:481.e1-7.
123. Ogburn JA, Espey E, Stonehocker J. Barriers to intrauterine device insertion in postpartum women. Contraception 2005; 72:426-9.
124. Parlier AB, Fagan B, Ramage M, Galvin S. Prenatal care, pregnancy outcomes, postpartum birth control plans among pregnant women with opiate addictions. South Med J 2014;107:676-83.
125. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007;32:19-25.
126. Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, et al. Opioid dependence during pregnancy: Relationships of anxiety and depression symptoms to treatment outcomes. Addiction 2012;107(suppl 1):74-82.
127. Chapman SL, Wu LT. Postpartum substance use and depressive symptoms: A review. Women Health 2013;53:479-503.
128. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: Assessment and management. Addict Dis 1975;2:141-58.
129. Lipsitz PJ, Blatman S. Newborn infants of mothers on methadone maintenance. N Y State J Med 1974;74:994-9.
130. Jansson LM, Velez ML. Infants of drug-dependent mothers. Pediatr Rev 2011;32:5-12.
131. Hudak ML, Tan RC; Committee on Drugs; Committee on the Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012;129:e540-60.
132. Ostrea EM Jr, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. Addict Dis 1975;2:187-99.
133. Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: A device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981;8:203-13.
134. Zahorodny W, Rom C, Whitney W, Giddens S, Samuel M, Maichuk G, et al. The neonatal withdrawal inventory: A simplified score of newborn withdrawal. J Dev Behav Pediatr 1998;19:89-93.
135. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: Assessment and pharmacologic management. J Opioid Manag 2009;5:47-55.
136. Wachman EM, Newby PK, Vreeland J, Byun J, Bonganzi A, Bauchner H, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011;5:293-9.
137. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, et al. Association of OPRM1 and COMT singlenucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013;309:1821-7.
138. Wachman EM, Hayes MJ, Lester BM, Terrin N, Brown MS, Nielsen DA, et al. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 2014;165:472-8.
139. Patrick SW, Schumacher RE, Horbar JD, Buus-Frank ME, Edwards EM, Morrow KA, et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016 [Epub ahead of print].
140. Velez M, Jansson LM. The Opioid dependent mother and newborn dyad: Non-pharmacologic care. J Addict Med 2008; 2:113-20.
141. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015;372:2118-26.
142. Asti L, Magers JS, Keels E, Wispe J, McClead RE Jr. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. Pediatrics 2015;135:e1494-500.
143. Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: A systematic review and meta-analysis [published erratum appears in BMC Psychiatry 2015;15:134].
144. BMC Psychiatry 2014;14:104